171233-40-2

Basic information

• Product Name: Tezacitabine
• Synonyms: Tezacitabine
• CAS NO: 171233-40-2
• Molecular Formula: C10H12FN3O4
• Molecular Weight: 257.2183832
• Mol File: 171233-40-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tezacitabine(CAS DataBase Reference)
• NIST Chemistry Reference: Tezacitabine(171233-40-2)
• EPA Substance Registry System: Tezacitabine(171233-40-2)

Safety Data

• Hazardous Substances Data: 171233-40-2(Hazardous Substances Data)

Upstream product

• 135789-88-7 (Z)-1-<2-deoxy-2--3,5-O-<1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl>-β-D-erythro-pentofuranosyl>-4-ethoxy-2(1H)-pyrimidinone 
• 149008-04-8 C₃₄H₆₄FN₃O₅Si₂Sn 
• 135789-90-1 (E)-1-<2-deoxy-2-(fluoromethylene)-3,5-O-<1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl>-β-D-erythro-pentofuranosyl>cytosine 
• 135789-89-8 (E)-1-<2-deoxy-2--3,5-O-<1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl>-β-D-erythro-pentofuranosyl>-4-ethoxy-2(1H)-pyrimidinone 
• 132619-20-6 (E)-1-<2-deoxy-2--3,5-O-<1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl>-β-D-erythro-pentofuranosyl>-4-ethoxy-2(1H)-pyrimidinone 
• 132619-21-7 (Z)-1-<2-deoxy-2--3,5-O-<1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl>-β-D-erythro-pentofuranosyl>-4-ethoxy-2(1H)-pyrimidinone 
• 113648-22-9 4-ethoxy-1-<3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-erythro-2-pentulofuranosyl>-2(1H)-pyrimidinone 

Relevant articles and documents

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

EFFICIENT NUCLEOTIDE SYNTHESIS

In one aspect, an improved synthesis for the anticancer drug tezacitabine comprises a hydroxyl deprotection reaction of vinyl stannane at a temperature of 45°C or greater, preferably about 55°C. In another aspect, the aqueous reaction product of hydroxyl deprotection is passed through a carbon filter prior to water crystallization to recover tezacitabine monohydrate from the aqueous medium. The process of the present invention significantly improves efficiency by greatly reducing the amount of time required for the synthesis of tezacitabine, and also provides improved product yields.

Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides

This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease stat

2-'-ethenylidene cytidine, uridine and guanosine derivatives

This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease stat

2'-halomethylidene cytidine, uridine and guanosine compounds and their pharmaceutical compositions

This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease stat